Increasing evidence disclosed the existence of a novel multi-organ endocrine pathway, involving bone, pancreas and testis, of high penetrance in energy metabolism and male fertility. The main mediator of this axis is undercarboxylated osteocalcin (ucOC), a bonederived protein-exerting systemic effects on tissues expressing the metabotropic receptor GPRC6A. The recognized effects of ucOC are the improvement of insulin secretion from the pancreas, the amelioration of systemic insulin sensitivity, in particular in skeletal muscle, and the stimulation of the global endocrine activity of the Leydig cell, including vitamin D 25-hydroxylation and testosterone production. The supporting evidence of this circuit in both animal and human models is here reviewed, with particular emphasis on the role of ucOC on testis function. The possible pharmacological modulation of this hormonal circuit for therapeutic aims is also discussed.
INTRODUCTION
The regulation of testis function is classically ascribed to the hypothalamic-pituitary-gonadal axis. According to this endocrine pathway, the hypothalamic release of gonadotropin-releasing hormone (GnRH) stimulates the production of the two gonadotropins, namely, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), by the adenohypophysis. Subsequently, FSH and LH act on the testis by stimulating, respectively, the spermatogenesis and the production of testosterone (T) that, in turn, inhibits both GnRH an gonadotropins release with a negative feedback loop (reviewed in Du Plessis et al., 2010) .
Recent studies revealed the existence of a parallel endocrine pathway acting on the endocrine function of the testis, which involves a bone-derived hormone, osteocalcin (OC). OC is a non-collagenous protein of osteoblast origin, highly represented in the bone extracellular matrix and actively involved in bone formation (Ducy et al., 1996) . Indeed, OC influences the hydroxyapatite nucleation because of its high affinity for calcium ions, a property gained by the vitamin K-dependent ccarboxylation of three Gla residues at positions 17, 21 and 24 (Hauschka et al., 1989; Hunter et al., 1996; Hoang et al., 2003; Cristiani et al., 2014) . However, a decarboxylation process of OC has been described to take place in vivo, resulting in the formation of the 17-undercarboxylated form of OC (ucOC) detected both within the bone extracellular matrix and in the bloodstream (Delmas, 1993; Ferron et al., 2010; Oury et al., 2013) . Indeed, circulating levels of ucOC can be quantified by dedicated immunoassays and generally account for approximately the 20-30% of the total serum OC that, on the other hand, comprises a wider range of OC forms, from the carboxylated to the undercarboxylated and other related peptides (Razny et al., 2016) . This chemical modification shifts the target tissue of OC from the bone to extra-osseous organs, where ucOC was demonstrated to exert a variety of regulating function: from male fertility to steroidogenesis and energy metabolism, thus outlining a new pancreas-bone-testis axis (Oury et al., 2013) . In particular, the mediator of ucOC activity in target tissues was recognized as the metabotropic G proteincoupled membrane-receptor GPRC6A. Since its original observation in animal models, the consistence of this hormonal pathway has been extended also to human and the implication of OC action, with particular focus on testis function, is here reviewed.
GPRC6A: characterization, expression and function
From its original cloning in 2004 (Wellendorph & Br€ aunerOsborne, 2004) , GPRC6A was readily de-orphanized and characterized. Major information on its structure and conformation derive from homology analysis of the available X-ray structures of the phylogenetically nearest receptors, such as metabotropic glutamate receptors 1 and 3 and b2-adrenergic receptor (Wellendorph & Br€ auner-Osborne, 2004; Br€ auner-Osborne et al., 2007; Rondard et al., 2006) . The most abundant variant of GPRC6A corresponds to a 926 amino-acids protein and, in agreement with other members of the class C GPCRs family, the presence of a Venus flytrap (VFT) domain, a cysteine-rich domain (CRD) and seven transmembrane domains (7TM) has been modelled. Early experiments showed that the receptor senses a relatively wide variety of L-a-amino acid. In particular, basic L-amino acids like arginine, lysine and ornithine display higher activating power compared to aliphatic amino acids (Christiansen et al., 2006) . In addition, also metal ions like calcium showed a dose-dependent agonist activity on GPRC6A. In fact, calcium concentrations lower than 5 mM augments receptor's responses to amino acids, whereas concentrations higher than 5 mM displayed a direct agonist activity (Kuang et al., 2005; Pi et al., 2005) . From a mechanistic point of view, membrane GPRC6A is thought to organize and operate as a dimer (Kuang et al., 2005) . According to this model, the agonist would bind to the cleft within the extracellular VFT domain, promoting a conformational closure of this portion and a subsequent torsion between the functional interfaces of the dimer (Jensen et al., 2002) . This conformational rearrangement would spread towards the 7TM domain through the poorly flexible VFT-CRD interaction, with the consequent activation of the cytoplasmic portion of the protein (Rondard et al., 2006) .
Early insights on the role of GPRC6A derive from its expression in human. Indeed, GPRC6A mRNA has been identified in brain, lung, liver, heart, kidney, pancreas, skeletal muscle, placenta, spleen, ovary, prostate, leucocyte, monocyte and testis (Wellendorph & Br€ auner-Osborne, 2004; Kuang et al., 2005; Pi & Quarles, 2012; Rossol et al., 2012) . It should be noted that most of the GPRC6A-expressing tissues were involved in energy metabolism and, accordingly, early reports on GPRC6A À/À animal models showed an involvement of multiple organs and metabolic functions. In particular, the complex phenotype of GPRC6A À/À mice consisted of: defective bone mineralization and impaired osteoblast function in male and female mice, a decrease in lean body mass, an increase in fat mass, hyperphosphatemia and hypercalciuria, hyperglycaemia and feminization of male mice associated with altered ratio of estradiol to T, suggesting that GPRC6A is involved in hormonal regulation of energy metabolism (Pi et al., 2008) . Despite the possible role of GPRC6A as a receptor of ucOC was originally suggested by Pi et al. in 2005 (Pi et al., 2005 (Pi et al., 2008; Oury et al., 2013) , whereas only recently, molecular proofs of the direct interaction between ucOC and GPRC6A have been provided by both the group of Pi et al. and our group (De Toni et al., 2016a,b; Pi et al., 2016) . A conclusive profiling of the hormonal pathway involving GPRC6A and ucOC in mouse model has been recently disclosed by the group of Karsenty et al. in 2013 (Oury et al., 2013 . According to this model, OC produced by osteoblasts is converted into ucOC by osteoclasts through acidification of bone resorption lacunae. This process is under the control of the insulin-signalling pathway in osteoblasts. Once released in the bloodstream, ucOC is able to achieve its hormonal activity on key cell populations expressing GPRC6A in target tissues, in particular the Leydig cells in the testis and Langherans b-cells in the endocrine pancreas. On one hand, in parallel with LH signalling, ucOC stimulates the production of T from Leydig cells with a major impact on semen parameters and male fertility (Oury et al., 2011 (Oury et al., , 2013 . On the other hand, ucOC stimulates b-cell proliferation and insulin release, improving in turn the OC decarboxylation in bone through a positive feedback loop (Oury et al., 2013; Karsenty & Oury, 2014) (Fig. 1) . Importantly, ucOC also mediates insulin sensitivity in peripheral tissues such as skeletal muscle and adipose tissue. In fact, it has been recently demonstrated that ucOC directly promotes glucose uptake and correct trophysm in skeletal muscle in a GPRC6A-mediated pathway (Tsuka et al., 2015; Mera et al., 2016a,b) . In adipose tissue, GPRC6A mediates the ucOC-dependent production of adiponectin, thus indirectly contributing to insulin sensitivity (Ferron et al., 2008; Otani et al., 2015) (Fig. 1 ). The consistency of this hormonal axis has been then investigated also in humans and the resulting clinical consequences will be further discussed in the following chapters.
Influence of the OC/GPRC6A axis on the testis
Bone is a dynamic tissue undergoing modelling and remodelling from childhood throughout adult life as a result of the balance between resorption of mineralized bone by osteoclasts and de novo formation by osteoblasts (Rodan & Martin, 2000; Harada & Rodan, 2003) . One of the most powerful hormonal regulations of bone remodelling is exerted by sex steroid hormones that are necessary to maintain bone integrity (reviewed in Vanderschueren et al., 2014) . In fact, it is widely acknowledged that male and female patients with gonadal failure are characterized by low bone mass (Wishart et al., 1995; Riggs et al., 1998) . The study of the interplay between gonads and bone has classically focused on the mechanism, whereby sex steroid hormones affect bone mass accrual, but major cues of a coordinated regulation of bone mass, energy metabolism and reproduction are matters of a relatively recent past. Original observation from Oury et al. documented that osteocalcin-deficient male mice were poor breeders and had reduced levels of T. Accordingly, mouse primary Leydig cells cultures increased the release of T after stimulation with uncarboxylated OC in a dose-dependent manner, whereas direct administration of OC in WT mice resulted in increased levels of T (Oury et al., 2011) . On the other hand, the analysis of the reproductive phenotype of Ocn À/À and Esp À/À male mice, being Esp À/À mice the animal model with over-representation of circulating ucOC (Lee et al., 2007) , showed a strict correlation between serum levels of T and ucOC. Moreover, when Ocn À/À male mice were mated with wild-type female mice, litter size was severely reduced compared with wild-type male controls. Conversely, offspring number significantly increased when Esp À/À males were mated with wild-type female mice (Oury et al., 2011) . Importantly, female fertility was not affected in these animal models. Further elucidation of the molecular bases of OC showed that the molecular target of this bone protein is GPRC6A, whose expression in the testis is essentially confined to Leydig cells. Indeed, in conditioned-Leydig Gprc6a À/À male mice, the size and weight of testes, epididymis and seminal vesicles, together with sperm count, circulating T levels and Leydig cell representation were all reduced. According to this model, ucOC would act on GPRC6A through a CREB-mediated pathway, directly inhibiting Leydig cell apoptosis and stimulating steroidogenesis and T production (Oury et al., 2011) . On the other hand, in global GPRC6A À/À mice multiple organs and metabolic functions were affected, but the most striking feature was the feminization of male GPRC6A À/À mice, consisting of reduced T levels, increased oestrogens and reduced ano-genital distance (Pi et al., 2008) . Such a phenotype resembles the androgen receptor-null and testicular-feminized mouse models, even though less severe (Yeh et al., 2002) .
Subsequent studies aimed to identify the consistency between animal and human models. As a result, there is a general consensus that circulating levels of ucOC are related to testis function. Association between serum levels of ucOC and T was investigated by Kirmani et al. in 56 boys aged 7-21 years and positive association was found for bone age from 11 to 14 years (Kirmani et al., 2011) . Also Kanazawa et al., (2013) reported a positive correlation between both ucOC and ucOC/total OC ratio with free T in patients with type 2 diabetes mellitus. More recently, analogue associations were found in a wide range of male subjects, from the general population, to patients with osteoporosis, metabolic syndrome or obesity (Foresta et al., 2011a,b; Buday et al., 2013; Hannemann et al., 2013; Samavat et al., 2014) . However, inconsistencies have also been reported in two studies on cohorts of elderly men (Limonard et al., 2015; Figure 1 The multi-organ hormonal circuit, involving bone, testis and pancreas, suggested to regulate energy metabolism and male fertility. According to this model, carboxylated osteocalcin (OC) in the bone extracellular matrix is decarboxylated into undercarboxylated OC (ucOC) and released in the bloodstream where it exerts systemic effects on tissues-expressing GPRC6A, the recognized receptor of ucOC. On pancreas, ucOC stimulates Langerhans b-cells (b-Cells) proliferation and improves insulin (Ins) secretion. In turn Ins, acting through the insulin receptor (InsR), promotes the decarboxylation of OC in the bone, by enhancing the acidification of extracellular matrix in resorption lacunae operated by osteoblasts. This effect is ascribed to the InsR-dependent inhibition of osteoprotegerin (Opg) release by osteoblasts. The consequent reduction in the Opg/Receptor activator of nuclear factor kappa-B ligand (RANKL) ratio triggers the bone-remodelling activity of osteoblasts. On adipose tissue, ucOC stimulates the production of adiponectin that ameliorates systemic insulin sensitivity, in particular, in skeletal muscle. Skeletal muscle itself is a target tissue of ucOC, being stimulated for mass maintenance and metabolic proficiency. Together with the luteinizing hormone (LH)/LH-receptor (LHR) axis, ucOC stimulates the global endocrine activity of the Leydig cell, including Vit D 25-hydroxylation (25OHVitD) and testosterone (T) production. The possible role of ucOC on INSL3 production by Leydig cells has not been investigated yet. In turn T, and likely INSL3, stimulates spermatogenesis within the seminiferous tubule, whereas 25OHVitD, T and INSL3 display a recognized positive effect on bone formation. The known effects of Leydig cell hormones on adipocytes and skeletal muscle metabolism have not been indicated. Discontinuous arrows indicate the hormone release. Continuous arrows indicate an overall effect on the whole tissue.
666 Andrology, 2017, 5, 664-670 Yeap et al., 2015) , and in a report from Schwetz et al., (2013) on young male adults from infertile couples, showing a weaker association between ucOC and T.
The endocrine function of Leydig cells relies beyond the sole production of T, involving INSL3 release and, as recently hypothesized, the vitamin D (VitD) activation into 25-hydroxy Vitamin D (25OH VitD) (Ferlin et al., 2013) . To this regard, the main enzyme responsible for the initial 25-hydroxylation in VitD activation has been recently identified as CYP2R1 (reviewed in Thacher & Levine, 2016) . Interestingly, the expression of this cytochrome has been detected at high levels in the liver and in Leydig cells in the testis (Bi eche et al., 2007; Blomberg Jensen et al., 2010; Foresta et al., 2011a,b) . In a recent study we showed that, parallel to the stimulation of T production, ucOC was able to increase CYP2R1 protein expression and VitD 25-hydroxylation in MA-10 murine Leydig cell line (Fig. 1) . In particular, this effect was specific of GPRC6A, whose stimulation was associated with rapid extracellular calcium trafficking. Accordingly, we have shown that, in a small group of male subjects with different body mass index (BMI), both serum levels of ucOC and the ucOC/total OC ratio positively and significantly correlated with 25OH Vit D levels, with the ucOC/total OC ratio resulting an independent predictor of serum 25OH Vit D in a multiple stepwise regression analysis . Further studies are required to confirm these preliminary observations and to address the contribution of this pathway on the overall pool of circulating 25OH Vit D.
A conclusive demonstration of the involvement of the OC/ GPRC6A in the regulation of testis function in humans has been recently provided by the description of two individuals harbouring a rare heterozygous missense variant in the extracellular domain of GPRC6A (F464Y), which prevents the receptor from localizing to the cell membrane and blunts its signalling pathway (Oury et al., 2013) . Interestingly, the clinical features of these patients were compatible with a condition of testicular insufficiency, characterized by subfertility, altered sperm parameters, low circulating T levels and high circulating LH levels. Moreover, one of the two patients had history of unilateral cryptorchidism. Furthermore, additional evidence supporting the involvement of GPRC6A in the reproductive system derived from a genomewide association study where, in a cohort of 4376 prostate cancer patients and 7545 controls, the coding SNP mostly associated with prostate cancer was the common NS variant rs2274911 (Pro91Ser) in the GPRC6A gene, with the minor allele G (MAFs of 24-43%) showing a protective effect (Haiman et al., 2013) . On these bases, we assessed the distribution of both rs2274911 polymorphism and F464Y mutation in a cohort of patients affected by infertility and/or cryptorchidism. Notably, we reported that the risk allele A in GPRC6A was associated with increased LH levels and almost doubled the risk of impairment of spermatogenesis. Furthermore, newborns with cryptorchidism carried rs2274911 variant at higher frequency compared with general population. In addition, by the use of an in vitro model, we showed that the A allele, either in homozygosity or heterozygosity, was associated with a lower exposition of the receptor on cell membrane and a reduced downstream phosphorylation of ERK1/2 (De Toni et al., 2016a,b) .
Taken together all these data support the hypothesis, consistent in both mice and humans, that Leydig cells are the target of two main hormonal axes: the LH/LH-receptor and the OC/ GPRC6A. Both circuits contribute to stimulate Vit D 25-hydroxylation, T production and spermatogenesis. Unbalance on the ucOC/GPRC6A axis, resulting from reduced ucOC levels or genetic variants associated with GPRC6A inactivation or subfunction, is likely linked to reduced exposure to androgens with increased risk to develop maldescent of the testis during foetal life (cryptorchidism) and/or low sperm production in adulthood. Whether this dual axis acts also on INSL3 is currently unknown. This aspect would represent an interesting field of investigation, considering the role of INSL3 on the cross-talk between bone and testis (Ferlin et al., 2008) .
Systemic influence of the OC/GPRC6A axis As cited above, it is now clear that the OC/GPRC6A is involved in a multi-organ endocrine pathway with major systemic involvement. Early report from Lee et al., (2007) showed a primary role of OC in the regulation of energy metabolism, as Ocn À/À and Esp À/À mice showed, respectively, increased and reduced propensity to develop metabolic derangements. Accordingly, in a following study in 2010, the group of Karsenty et al. clarified the signalling pathway subtending the control of energy metabolism through OC decarboxylation (Ferron et al., 2010) . According to this model ( Fig. 1) , insulin (Ins) would inhibit osteoprotegerin (Opg) release from the osteoblast through a classical Ins receptor (InsR)-mediated pathway. In turn, free from the inhibitory effect of Opg on the RANK/RANK-L system, bone remodelling would take place in resorption lacunae by osteoclasts through acid secretion in extracellular matrix. As a result of environmental pH lowering, OC is decarboxylated, gets released by hydroxyapatite by the loss of its affinity for calcium and enters the bloodstream exerting systemic effects (Cristiani et al., 2014) . To this regard, the specific action of OC on the different target tissues expressing GPRC6A has been disclosed by several independent investigations with major attention devoted to pancreas b-cells. Ferron et al., (2008) reported that wild-type mice treated for 28 days with recombinant ucOC were protected from alterations in glucose metabolism, insulin sensitivity, lipid profile and weight gain associated with high-fat diet. In particular, dose-response stimulation in isolated primary cell cultures showed that ucOC induced a specific up-regulation of insulin gene expression and CyclinD2-dependent b-cell proliferation. Detailed molecular aspects of the role of OC/GPRC6A in b-cells have been further investigated by Pi et al., (2016) by the development of mice with conditional deletion of GPRC6A gene in bcells. In agreement with previous studies, conditioned-b-cell GPRC6A À/À mice exhibited altered glucose tolerance as a result of diminished insulin secretion, reduced pancreatic insulin content associated with reduced size and number of proliferating islets. Furthermore, ucOC has been found to potentiate insulin secretion through the inhibition of Kv channels and consequent increase in intracellular calcium, a mechanism involving phospholipase-C (PLC)/protein kinase C (PKC)/Ras/MAPK-ERK kinase (MEK) signalling pathway in isolated rat pancreatic cells . In addition to the improvement of the endocrine function of pancreas, ucOC was found to ameliorate insulin sensitivity of several organs with metabolic relevance, through both a direct and an indirect action. In fact, adipose tissue is a target of OC action and, as initially reported by Ferron et al., stimulation with ucOC increased gene expression of adiponectin, PGC1-a and UCP-1 genes in cultured primary adipocytes. (Ferron et al., 2008) . Accordingly, Otani et al., using in an in vitro model of differentiated mouse 3T3-L1 adipocytes cell line, demonstrated that ucOC up-regulates the expression of peroxisome proliferator-activated receptor c (PPARc), which in turn induces adiponectin expression. Interestingly, authors also defined the signalling pathway activated by ucOC through GPRC6A, involving cAMP/PKA/CREB/ERK/Src (Otani et al., 2015) . The release of adiponectin from adipose tissue has an acknowledged role on the suppression of glucose production in the liver and the increase in fatty acid oxidation in skeletal muscle, which together contribute to a beneficial metabolic action in wholebody energy homeostasis (reviewed in Wang & Scherer, 2016) . In addition, Mera et al., (2016a,b) recently demonstrated that ucOC signalling in skeletal muscle fibres favours the breakdown of glycogen, a major source of glucose for contracting muscles during exercise. Furthermore, it promotes the translocation of the glucose transporter GLUT4 to the plasma membrane, thereby enhancing glucose uptake and glycolysis, while increases fatty acids uptake and catabolism. Through these combined functions, the signalling of ucOC provides the carbon atoms necessary to promote and maintain muscle function.
In order to extend these aspects in humans, reduced levels of circulating ucOC have been observed by different authors in patients of both sexes with metabolic derangements. Our group in 2010 observed that overweight and obese male patients had a lower ucOCN and ucOC/OCN ratio and, in the whole cohort, ucOCN/OCN ratio was negatively correlated with BMI (Foresta et al., 2010) . Also the group of Kanazawa et al., (2011a,b) in two different studies reported significant and inversed association between low-serum ucOC levels and homeostasis model assessment (HOMA) for insulin resistance in patients of both sexes. More recently, Razny et al., (2016) reported that ucOC was negatively associated with fasting insulin levels and was reduced in pre-diabetic individuals compared to healthy obese volunteers. Lee et al., (2015) , focusing on a group of post-menopausal females, found that ucOC was negatively correlated with altered lipid profile, fasting insulin, HOMA-IR, and serum leptin and was positively correlated with serum adiponectin.
Interestingly, an increasing number of reports shows a significant association between genetic variants of either the OC or the GPRC6A genes and risk to develop cardio-metabolic diseases. Based on the original observation that male patients with the rare mutation F464Y of the GPRC6A gene exhibited metabolic syndrome characterized by an increase in BMI, elevated waist circumference, dyslipidemia and glucose intolerance (Oury et al., 2013) , we investigated the possible involvement of the rs2274911 polymorphism of the GPRC6A gene in metabolic derangements. Accordingly, we showed that despite the distribution of alleles and genotypes did not differ either between normal weight and obese subjects or sexes, in normal weight subjects the risk allele A was associated with increased fasting insulin and HOMA-IR (Di Nisio Clin Endocrinol (Oxf). 2016). These associations were even strengthened in obese subjects where AA homozygotes showed also altered lipid profile, suggesting that the polymorphism may not represent a causal effector, but rather pre-dispose individuals to the development of insulin resistance, independently of the metabolic background (Di Nisio et al., 2016) . Intriguingly, the common polymorphism rs1800247 of the OC gene, associated with reduced circulating levels of OC, has been recently related to significant increase in blood pressure in patients of both sexes, regardless of HOMA-IR (Ling et al., 2016a,b) .
CONCLUSION AND FUTURE PERSPECTIVES
During the last 10 years, an increasing number of reports concurred to identify a novel multi-organ hormonal pathway, including bone, testis and pancreas, of high penetrance in energy metabolism and male fertility (Fig. 1) . According to this model, carboxylated osteocalcin in the bone extracellular matrix is partially decarboxylated into undercarboxylated OC and released in the bloodstream where it exerts systemic effects on tissues-expressing GPRC6A, the recognized receptor of ucOC. On pancreas, ucOC improves insulin secretion that, in turn, promotes decarboxylation of OC in the bone. On adipose tissue, ucOC stimulates the production of adiponectin that ameliorates systemic insulin sensitivity, in particular in skeletal muscle. Skeletal muscle itself is a target tissue of ucOC, being stimulated for mass maintenance and metabolic proficiency. Finally, together with LH, ucOC stimulates the global endocrine activity of the Leydig cell, including Vit D 25-hydroxylation and T production that, together with INSL3, have in turn important roles in bone and energy metabolism (Fig. 1) . Originally investigated in mice and in vitro models, this pathway was confirmed to some extent in human males, remaining, however, a matter of debate.
The possible pharmacological modulation of this hormonal pathway represents an attractive perspective for the treatment of both male infertility and metabolic diseases, included agerelated sarcopenia. To this regard, recent studies aimed to improve both metabolic derangements and male hypogonadism through oral administration of ucOC in animal models (Mizokami et al., 2014 (Mizokami et al., , 2016 . However, despite the undoubted value of these pioneer studies, the high variable response expected from the oral administration of a therapeutic protein renders this approach unlikely. The availability of proper computational models of GPRC6A (De Toni et al., 2016a,b; Pi et al., 2016) may instead represent a suitable platform to develop new small molecules with possible agonist or antagonist properties. Therefore, in this direction, the best has still to come.
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